We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Supercomputer Offers Advanced Algorithms to Develop Predictive Models of Disease

By LabMedica International staff writers
Posted on 29 Apr 2013
Print article
After one year of operation, a USD 3 million supercomputer is a large step forward in constructing a substantial computational and data-intensive infrastructure designed specifically for genomics.

Mount Sinai Hospital (New York, NY, USA) is one of the first academic medical centers in the United States to build and operate a supercomputer. Minerva, named after the Roman goddess of wisdom and medicine, utilizes cutting-edge computer algorithms to develop predictive models of disease that can better help diagnose and treat patients.

Built on-site by Mount Sinai’s department of scientific computing, Minerva analyzes the growing “digital universe,” including genomic and phenotypic data, as well information from electronic medical records (EMRs). It has already analyzed hundreds of human genome sequences with a projection of hundreds of thousands yearly. With thousands of processing cores working together, and tens of terabytes of memory, the supercomputer can perform complicated and sophisticated tasks rapidly and with more precision than ever before.

“With Minerva, Mount Sinai has the ability to quickly analyze genomic patterns to provide a greater understanding of the causes of disease and how to personalize treatments according to an individual’s genetic composition,” said Dennis S. Charney, MD, dean of the Icahn School of Medicine at Mount Sinai. “The supercomputer is able to accomplish real-time visualization of advanced molecular models, promoting drug development and allowing us to test the effects of molecular variations on different receptors in the body.”

The supercomputer also stores data from Mount Sinai’s biobank, called BioME, a collection of over 24,000 individuals’ DNA and plasma samples that are stored in a way that protects patients’ privacy while allowing research to be performed. The biobank accesses a wide range of genetic and environmental data on patients who have agreed to participate throughout their lives.

“The supercomputer is helping us better understand and foresee the course of disease for each patient, and to identify the outcome to a particular therapeutic intervention in advance,” said Patricia Kovatch, associate dean for scientific computing at Mount Sinai Medical Center and the engineer who constructed Minerva. “Thus, using genomic data, information from our biobank as well as complex simulations of molecules, we are able to enhance personalized medicine to a degree that has never been done before.”

Eric Schadt, PhD, Mount Sinai’s director of the Institute for Genomics and Multiscale Biology, cited the need for Minerva in critical areas of research that is already underway. “In order to analyze and integrate all the different data dimensions over the population, and build predictive models of disease, we need the supercomputer. With the infrastructure we’re creating, and the people we’ve recruited, combined with the resources already available at Mount Sinai, we are coming together to form a new epicenter of research on personalized medicine and the new biology.”

“Few research centers have the type of computing infrastructure to allow advanced modeling that Mount Sinai can now do on-site. Along with other advances in genetics and some recent outstanding additions to our faculty, Minerva further cements Mount Sinai’s reputation at the forefront of the ‘precision medicine’ movement,” said Dr. Charney.

Joseph Buxbaum, PhD, director of the Mt. Sinai’s Seaver Autism Center for Research and Treatment, according to Minerva’s supercomputing capacity plays a key role in analyzing data gathered as part of the Autism Sequencing Consortium, a multinational collaboration where all the 22,000 genes in humans will be sequenced in thousands of individuals with autism spectrum disorder. “The consortium plans to have such data for as many as 30,000 people, including controls, over the next three years, and we anticipate that this will result in the discovery of several hundred autism genes. Without Minerva’s computational power, a project of this scope would simply not be feasible.”

To date, tens of millions of core processing hours of research has been performed by Minerva, added Dr. Kovatch. “The computer has helped scientists publish over 25 research articles. Minerva helps scientists analyze their data quicker than ever before, as well as complete more complex tasks simultaneously. The end result is that more science, even basic science, is done quicker and more efficiently.”

Related Links:
Mount Sinai Hospital



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.